Cargando…
ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes
INTRODUCTION: & BACKGROUND: Diabetes in COVID-19 patients is individual risk factor and documented in worldwide studies to contribute to disease severity, increased length of stay and higher mortality (fig-1). Aggressive management of blood sugars and acute diabetic complications reduce the leng...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624690/ http://dx.doi.org/10.1210/jendso/bvac150.686 |
_version_ | 1784822295706992640 |
---|---|
author | Bokhari, Samia Khan, Patan Shareef, Muneera A Safwat, Rania Galal, Mohamed Qadi, Hamdi Alzahrani, Ameerah Boraie, Rehab A Zahrani, Sara |
author_facet | Bokhari, Samia Khan, Patan Shareef, Muneera A Safwat, Rania Galal, Mohamed Qadi, Hamdi Alzahrani, Ameerah Boraie, Rehab A Zahrani, Sara |
author_sort | Bokhari, Samia |
collection | PubMed |
description | INTRODUCTION: & BACKGROUND: Diabetes in COVID-19 patients is individual risk factor and documented in worldwide studies to contribute to disease severity, increased length of stay and higher mortality (fig-1). Aggressive management of blood sugars and acute diabetic complications reduce the length of stay and mortality. METHODS: Randomly selected 200 patients admitted with diabetes and COVID-19 studied. The unified treatment protocol (fig-2) applied for all patients and blood sugars monitored closely and optimized. Data collected on bimonthly basis and analyzed. Patients’ characteristics taken from data extraction tool (Oasis) of hospital. Median values for length of stay and post discharge FBS and RBS were calculated Microsoft Excel tool. Mortality rates calculated by percentages. RESULTS: 200 patients studied in the 4 months study period. The median length of stay was 3 days. The mortality rate was 2.5% (fig-3,4). The median FBS and RBS in the patient group monitored in the post discharge clinic was 130 mg/dl and 170 mg/dl respectively. The results compared with the standard international studies. DISCUSSION: Diabetes in COVID-19 patients posed great challenge as increased severity and mortalities reported compared to non-diabetic. Taking a pre-emptive strategy to combat this problem by aggressively manage diabetes help in reducing length of stay and morbidity. The length of stay in studded population was 3 days as compared to 13 days in a major international study(Ref: 1) . Financial saving come from rapid turnover of beds. The mortality was 2.5% compared to reported 7.3% in a major study (Ref: 2), reflecting the implications of aggressive management of diabetes. Regular follow-up and support by running post-discharge clinic definitely help reducing readmissions and acute complications of uncontrolled diabetes. CONCLUSION: Aggressive management of diabetes in COVID-19 patients by tailored treatment protocols and dedicated teams will help to decrease the morbidity and mortality. Presentation: No date and time listed |
format | Online Article Text |
id | pubmed-9624690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-96246902022-11-14 ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes Bokhari, Samia Khan, Patan Shareef, Muneera A Safwat, Rania Galal, Mohamed Qadi, Hamdi Alzahrani, Ameerah Boraie, Rehab A Zahrani, Sara J Endocr Soc Diabetes & Glucose Metabolism INTRODUCTION: & BACKGROUND: Diabetes in COVID-19 patients is individual risk factor and documented in worldwide studies to contribute to disease severity, increased length of stay and higher mortality (fig-1). Aggressive management of blood sugars and acute diabetic complications reduce the length of stay and mortality. METHODS: Randomly selected 200 patients admitted with diabetes and COVID-19 studied. The unified treatment protocol (fig-2) applied for all patients and blood sugars monitored closely and optimized. Data collected on bimonthly basis and analyzed. Patients’ characteristics taken from data extraction tool (Oasis) of hospital. Median values for length of stay and post discharge FBS and RBS were calculated Microsoft Excel tool. Mortality rates calculated by percentages. RESULTS: 200 patients studied in the 4 months study period. The median length of stay was 3 days. The mortality rate was 2.5% (fig-3,4). The median FBS and RBS in the patient group monitored in the post discharge clinic was 130 mg/dl and 170 mg/dl respectively. The results compared with the standard international studies. DISCUSSION: Diabetes in COVID-19 patients posed great challenge as increased severity and mortalities reported compared to non-diabetic. Taking a pre-emptive strategy to combat this problem by aggressively manage diabetes help in reducing length of stay and morbidity. The length of stay in studded population was 3 days as compared to 13 days in a major international study(Ref: 1) . Financial saving come from rapid turnover of beds. The mortality was 2.5% compared to reported 7.3% in a major study (Ref: 2), reflecting the implications of aggressive management of diabetes. Regular follow-up and support by running post-discharge clinic definitely help reducing readmissions and acute complications of uncontrolled diabetes. CONCLUSION: Aggressive management of diabetes in COVID-19 patients by tailored treatment protocols and dedicated teams will help to decrease the morbidity and mortality. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9624690/ http://dx.doi.org/10.1210/jendso/bvac150.686 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Diabetes & Glucose Metabolism Bokhari, Samia Khan, Patan Shareef, Muneera A Safwat, Rania Galal, Mohamed Qadi, Hamdi Alzahrani, Ameerah Boraie, Rehab A Zahrani, Sara ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes |
title | ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes |
title_full | ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes |
title_fullStr | ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes |
title_full_unstemmed | ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes |
title_short | ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes |
title_sort | odp236 reducing length of hospital stay and mortality in covid-19 patients with diabetes |
topic | Diabetes & Glucose Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624690/ http://dx.doi.org/10.1210/jendso/bvac150.686 |
work_keys_str_mv | AT bokharisamia odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes AT khanpatan odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes AT shareefmuneeraa odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes AT safwatrania odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes AT galalmohamed odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes AT qadihamdi odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes AT alzahraniameerah odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes AT boraierehaba odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes AT zahranisara odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes |